Subscribe to our Newsletters !!


    Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020

    Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical

    Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals

    Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune

    Novel medication could improve future and quality for patients with difficult to-treat malignant growths

    The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made

    Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients

    Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the

    Conceivable new anti-microbial created for drug-resistant pulmonary microorganism

    Scientists from Johns Hopkins University and Medicine have developed a potential new antibiotic for a pathogen that is notoriously resistant to drugs and often lethal for people with cystic fibrosis and other lung disorders. The pathogen, called Mycobacterium abscessus, is related to some better-known bacterium that causes tuberculosis and leprosy but has recently emerged as

    new cGMP plasmid DNA manufacturing facility construction announced by Thermo Fisher

    Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. The site will expand the company’s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer

    Drug-discovery collaboration discovers potential new antimalarial drug candidates

    Potential new antimalarial drug candidates are being developed through an protracted drug-discovery collaboration between Australian medical research institute WEHI and Janssen Pharmaceutica NV. The collaboration was facilitated by Johnson & Johnson Innovation. A collaborative research team discovered compounds with antimalarial activity within a collection of 80,000 drug-like molecules at the Janssen Jump-stARter Compound Library, a